p63/MT1-MMP axis is required for in situ to invasive transition in basal-like breast cancer

Oncogene

Volumn 35, Issue 3, 2016, Pages 344-357

  Lodillinsky, C ^a   Infante, E ^a   Guichard, A ^a   Chaligne R ^b   Fuhrmann, L ^a   Cyrta, J ^a   Irondelle, M ^a   Lagoutte, E ^a   Vacher, S ^c   Bonsang Kitzis, H ^c   Glukhova, M ^a   Reyal, F ^c   Bieche I ^c   Vincent Salomon, A ^b,c   Chavrier, P ^a  

^a CNRS   (France)

^b INSTITUT CURIE   (France)

^c INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; HORMONE RECEPTOR; MATRIX METALLOPROTEINASE 14; PROGESTERONE RECEPTOR; PROTEIN P63; CKAP4 PROTEIN, HUMAN; INTERSTITIAL COLLAGENASE; MEMBRANE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASAL LIKE BREAST CANCER; BASEMENT MEMBRANE; CELL INVASION; CELL MIGRATION; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR INVASION; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; BASAL CELL CARCINOMA; BIOSYNTHESIS; BREAST TUMOR; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; BASEMENT MEMBRANE; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MATRIX METALLOPROTEINASE 1; MEMBRANE PROTEINS; MICE; NEOPLASM INVASIVENESS; NEOPLASMS, BASAL CELL; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84955383716     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.87     Document Type: Article

References (59)

1. Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 2003; 3: 422-433.
2. Cowell CF, Weigelt B, Sakr RA, Ng CK, Hicks J, King TA et al. Progression from ductal carcinoma in situ to invasive breast cancer: revisited. Mol Oncol 2013; 7: 859-869.
3. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994; 370: 61-65.
4. Tsunezuka Y, Kinoh H, Takino T, Watanabe Y, Okada Y, Shinagawa A et al. Expression of membrane-type matrix metalloproteinase 1 (MT1-MMP) in tumor cells enhances pulmonary metastasis in an experimental metastasis assay. Cancer Res 1996; 56: 5678-5683.
5. Hotary KB, Allen ED, Brooks PC, Datta NS, Long MW, Weiss SJ. Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell 2003; 114: 33-45.
6. Szabova L, Chrysovergis K, Yamada SS, Holmbeck K. MT1-MMP is required for efficient tumor dissemination in experimental metastatic disease. Oncogene 2008; 27: 3274-3281.
7. Perentes JY, Kirkpatrick ND, Nagano S, Smith EY, Shaver CM, Sgroi D et al. Cancer cell-associated MT1-MMP promotes blood vessel invasion and distant metastasis in triple-negative mammary tumors. Cancer Res 2011; 71: 4527-4538.
8. Sabeh F, Ota I, Holmbeck K, Birkedal-Hansen H, Soloway P, Balbin M et al. Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP. J Cell Biol 2004; 167: 769-781.
9. Hotary K, Li XY, Allen E, Stevens SL, Weiss SJ. A cancer cell metalloprotease triad regulates the basement membrane transmigration program. Genes Dev 2006; 20: 2673-2686.
10. Wolf K, Wu YI, Liu Y, Geiger J, Tam E, Overall C et al. Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat Cell Biol 2007; 9: 893-904.
11. Monteiro P, Rosse C, Castro-Castro A, Irondelle M, Lagoutte E, Paul-Gilloteaux P et al. Endosomal WASH and exocyst complexes control exocytosis of MT1-MMP at invadopodia. J Cell Biol 2013; 203: 1063-1079.
12. Okada A, Bellocq JP, Rouyer N, Chenard MP, Rio MC, Chambon P et al. Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci USA 1995; 92: 2730-2734.
13. Nakada M, Nakamura H, Ikeda E, Fujimoto N, Yamashita J, Sato H et al. Expression and tissue localization of membrane-type 1, 2, and 3 matrix metalloproteinases in human astrocytic tumors. Am J Pathol 1999; 154: 417-428.
14. Sakakibara M, Koizumi S, Saikawa Y, Wada H, Ichihara T, Sato H et al. Membrane-type matrix metalloproteinase-1 expression and activation of gelatinase A as prognostic markers in advanced pediatric neuroblastoma. Cancer 1999; 85: 231-239.
15. Zhai Y, Hotary KB, Nan B, Bosch FX, Munoz N, Weiss SJ et al. Expression of membrane type 1 matrix metalloproteinase is associated with cervical carcinoma progression and invasion. Cancer Res 2005; 65: 6543-6550.
16. Ueno H, Nakamura H, Inoue M, Imai K, Noguchi M, Sato H et al. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas. Cancer Res 1997; 57: 2055-2060.
17. Jones JL, Glynn P, Walker RA. Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. J Pathol 1999; 189: 161-168.
18. Bisson C, Blacher S, Polette M, Blanc JF, Kebers F, Desreux J et al. Restricted expression of membrane type 1-matrix metalloproteinase by myofibroblasts adjacent to human breast cancer cells. Int J Cancer 2003; 105: 7-13.
19. Tetu B, Brisson J, Wang CS, Lapointe H, Beaudry G, Blanchette C et al. The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis. Breast Cancer Res 2006; 8: R28.
20. Muggerud AA, Hallett M, Johnsen H, Kleivi K, Zhou W, Tahmasebpoor S et al. Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer. Mol Oncol 2010; 4: 357-368.
21. Lee S, Stewart S, Nagtegaal I, Luo J, Wu Y, Colditz G et al. Differentially expressed genes regulating the progression of ductal carcinoma in situ to invasive breast cancer. Cancer Res 2012; 72: 4574-4586.
22. Cheung KJ, Gabrielson E, Werb Z, Ewald AJ. Collective invasion in breast cancer requires a conserved basal epithelial program. Cell 2013; 155: 1639-1651.
23. Polyak K, Hu M. Do myoepithelial cells hold the key for breast tumor progression? J Mammary Gland Biol Neoplasia 2005; 10: 231-247.
24. Hu M, Yao J, Carroll DK, Weremowicz S, Chen H, Carrasco D et al. Regulation of in situ to invasive breast carcinoma transition. Cancer Cell 2008; 13: 394-406.
25. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999; 398: 708-713.
26. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999; 398: 714-718.
27. Carroll DK, Carroll JS, Leong CO, Cheng F, Brown M, Mills AA et al. p63 regulates an adhesion programme and cell survival in epithelial cells. Nat Cell Biol 2006; 8: 551-561.
28. Awadelkarim KD, Callens C, Rosse C, Susini A, Vacher S, Rouleau E et al. Quantification of PKC family genes in sporadic breast cancer by qRT-PCR: Evidence that PKCiota/lambda overexpression is an independent prognostic factor. Int J Cancer 2012; 131: 2852-2862.
29. Behbod F, Kittrell FS, LaMarca H, Edwards D, Kerbawy S, Heestand JC et al. An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ. Breast Cancer Res 2009; 11: R66.
30. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006; 10: 515-527.
31. Westfall MD, Mays DJ, Sniezek JC, Pietenpol JA. The Delta Np63 alpha phosphoprotein binds the p21 and 14-3-3 sigma promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Wells syndrome-derived mutations. Mol Cell Biol 2003; 23: 2264-2276.
32. McDade SS, Henry AE, Pivato GP, Kozarewa I, Mitsopoulos C, Fenwick K et al. Genome-wide analysis of p63 binding sites identifies AP-2 factors as co-regulators of epidermal differentiation. Nucleic Acids Res 2012; 40: 7190-7206.
33. Buckley NE, Conlon SJ, Jirstrom K, Kay EW, Crawford NT, O'Grady A et al. The DeltaNp63 proteins are key allies of BRCA1 in the prevention of basal-like breast cancer. Cancer Res 2011; 71: 1933-1944.
34. Shekhar MP, Kato I, Nangia-Makker P, Tait L. Comedo-DCIS is a precursor lesion for basal-like breast carcinoma: identification of a novel p63/Her2/neu expressing subgroup. Oncotarget 2013; 4: 231-241.
35. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121: 2750-2767.
36. Harmes DC, Bresnick E, Lubin EA, Watson JK, Heim KE, Curtin JC et al. Positive and negative regulation of deltaN-p63 promoter activity by p53 and deltaN-p63-alpha contributes to differential regulation of p53 target genes. Oncogene 2003; 22: 7607-7616.
37. Lindsay J, McDade SS, Pickard A, McCloskey KD, McCance DJ. Role of DeltaNp63gamma in epithelial to mesenchymal transition. J Biol Chem 2011; 286: 3915-3924.
38. Olsen JR, Oyan AM, Rostad K, Hellem MR, Liu J, Li L et al. p63 attenuates epithelial to mesenchymal potential in an experimental prostate cell model. PLoS One 2013; 8: e62547.
39. Tucci P, Agostini M, Grespi F, Markert EK, Terrinoni A, Vousden KH et al. Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc Natl Acad Sci USA 2012; 109: 15312-15317.
40. Balboni AL, Hutchinson JA, DeCastro AJ, Cherukuri P, Liby K, Sporn MB et al. DeltaNp63alpha-mediated activation of bone morphogenetic protein signaling governs stem cell activity and plasticity in normal and malignant mammary epithelial cells. Cancer Res 2013; 73: 1020-1030.
41. Chakrabarti R, Wei Y, Hwang J, Hang X, Andres Blanco M, Choudhury A et al. DeltaNp63 promotes stem cell activity in mammary gland development and basal-like breast cancer by enhancing Fzd7 expression and Wnt signalling. Nat Cell Biol 2014; 16: 1004-1015 1-13.
42. Santner SJ, Dawson PJ, Tait L, Soule HD, Eliason J, Mohamed AN et al. Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. Breast Cancer Res Treat 2001; 65: 101-110.
43. Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol 2014; 232: 142-150.
44. Ribeiro-Silva A, Ramalho LN, Garcia SB, Brandao DF, Chahud F, Zucoloto S. p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer. Histopathology 2005; 47: 458-466.
45. Matos I, Dufloth R, Alvarenga M, Zeferino LC, Schmitt F. p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch 2005; 447: 688-694.
46. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006; 19: 264-271.
47. Prat A, Cheang MC, Martin M, Parker JS, Carrasco E, Caballero R et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol 2013; 31: 203-209.
48. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145.
49. Yu K, Lee CH, Tan PH, Hong GS, Wee SB, Wong CY et al. A molecular signature of the Nottingham prognostic index in breast cancer. Cancer Res 2004; 64: 2962-2968.
50. Vincent-Salomon A, Lucchesi C, Gruel N, Raynal V, Pierron G, Goudefroye R et al. Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast. Clin Cancer Res 2008; 14: 1956-1965.
51. Allred DC, Wu Y, Mao S, Nagtegaal ID, Lee S, Perou CM et al. Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res 2008; 14: 370-378.
52. Hannemann J, Velds A, Halfwerk JB, Kreike B, Peterse JL, van de Vijver MJ. Classification of ductal carcinoma in situ by gene expression profiling. Breast Cancer Res 2006; 8: R61.
53. Vincent-Salomon A, Pierga JY, Couturier J, d'Enghien CD, Nos C, Sigal-Zafrani B et al. HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management? Br J Cancer 2007; 96: 654-659.
54. Sakurai-Yageta M, Recchi C, Le Dez G, Sibarita JB, Daviet L, Camonis J et al. The interaction of IQGAP1 with the exocyst complex is required for tumor cell invasion downstream of Cdc42 and RhoA. J Cell Biol 2008; 181: 985-998.
55. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer 2010; 102: 1555-1577.
56. Teuliere J, Faraldo MM, Deugnier MA, Shtutman M, Ben-Ze'ev A, Thiery JP et al. Targeted activation of beta-catenin signaling in basal mammary epithelial cells affects mammary development and leads to hyperplasia. Development 2005; 132: 267-277.
57. Lohi J, Lehti K, Valtanen H, Parks WC, Keski-Oja J. Structural analysis and promoter characterization of the human membrane-type matrix metalloproteinase-1 (MT1-MMP) gene. Gene 2000; 242: 75-86.
58. Kouwenhoven EN, van Heeringen SJ, Tena JJ, Oti M, Dutilh BE, Alonso ME et al. Genome-wide profiling of p63 DNA-binding sites identifies an element that regulates gene expression during limb development in the 7q21 SHFM1 locus. PLoS Genet 2010; 6: e1001065.
59. Martynova E, Pozzi S, Basile V, Dolfini D, Zambelli F, Imbriano C et al. Gain-of-function p53 mutants have widespread genomic locations partially overlapping with p63. Oncotarget 2012; 3: 132-143.